BTIG Maintains Buy on Monopar Therapeutics, Raises Price Target to $117
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsPrice Target
BTIG analyst Jeet Mukherjee maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and raises the price target from $104 to $117.
BTIG analyst Jeet Mukherjee maintains Monopar Therapeutics (NASDAQ:MNPR) with a Buy and raises the price target from $104 to $117.